16 September 2017 in Neuro-Oncology
Glioblastoma (GBM) is the most common primary malignant brain cancer, and is currently incurable. Chimeric Antigen Receptor (CAR) T-cells have shown promise in GBM treatment. While we have shown that combinatorial targeting of two glioma antigens offsets antigen escape and enhances T-cell effector functions, the inter-patient variability in surface antigen expression between patients hinders the clinical impact of targeting two antigen pairs. This study addresses targeting 3 antigens using a single CAR T-cell product for broader application. We analyzed the surface expression of 3 targetable glioma antigens (HER2, IL13Rα2 and EphA2) in 15 primary GBM samples. Accordingly, we created a trivalent T-cell product armed with three CAR molecules specific for these validated targets encoded by a single universal (U) tricistronic transgene (UCAR T-cells). Our data showed that co-targeting HER2, IL13Rα2 and EphA2 could overcome inter-patient variability by a tendency to capture near 100% of tumor cells in most tumors tested in this cohort. UCAR T-cells made from GBM patients’ blood uniformly expressed all three CAR molecules with distinct antigen specificity. UCAR T-cells mediated robust immune synapses with tumor targets forming more polarized microtubule organizing centers (MTOC) and exhibited improved cytotoxicity and cytokine release over best monospecific and bispecific CAR T-cells per patient tumor profile. Lastly, low doses of UCAR T-cells controlled established autologous GBM patient derived xenografts (PDX) and improved survival of treated animals. UCAR T-cells can overcome antigenic heterogeneity in GBM and lead to improved treatment outcomes.
6 July 2010 in Acta Tropica
5 September 2018 in Nature
18 October 2010 in Planta Medica
Lymphatic filariasis, onchocerciasis, loaisis, and other helminth infections cause serious health problems especially in resource-limited tropical and subtropical developing countries of the world, and more than 2 billion people are infected with at least one helminth species. From times immemorial, man looked up to the plant kingdom in search of anthelmintics, antifilarials, and remedies for parasite-induced health problems. Although more than 50 % of drugs in modern medicine are derived from plants or leads from plants, a success story of plant-based anthelminthics or antifilarials is yet to be told. In the last 5 decades, more than 100 plant products were reported to be beneficial in the treatment or control of these parasitic infections but they could not be developed into viable drugs for a variety of reasons. This review focuses on the plant products reported to be useful in the control and treatment of human helminth infections with the main emphasis on filariasis and the in vitro and in vivo systems available for assaying anthelmintic activity.